Board to approve results for quarter and half year ended September 30, 2026

Results View source PDF Explain this filing

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹1001.10

prior close

₹1006.50

announcement price

After-mkt

timing

Nifty Microcap 250market+0.4%+2.4% vs market

Pharmaceuticals peers, median of 174sector+1.2%+1.6% vs sector

On the reaction day the stock moved 2.4 pts more than Nifty Microcap 250 and 1.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+1.5

15m

+2.1

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8+0.4+2.4+1.2+1.6

Next day

+8.5+2.1+6.4+3.1+5.4

+8.5pendingpending+4.7+3.8

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Strides Pharma Science Ltd will hold a Board meeting on October 29, 2026 to approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The trading window for designated persons is closed from October 1 until 48 hours after results are declared.

Likely market impact

The announcement schedules the results review but gives no earnings figures or outlook. Investor reaction will depend on the results declared on October 29.